Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
4 minute read

AstraZeneca, Merck Report Results From OlympiA Phase 3 Trial Of LYNPARZA For Patients With Germline Breast Cancer Gene-Mutated High-Risk Early Breast Cancer Showed Statistical Significance, Clinically Meaningful Improvement In Survival

By Benzinga Newsdesk
Today, 4:42 PM
First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced

AZN

Read More
3 minute read

Bristol Myers Squibb Offers Date From CheckMate -648 Showing Opdivo Plus Chemo And Opdivo Plus Yervoy Improved Overall Survival vs Chemo In Unresectable Advanced Or Metastatic Esophageal Squamous Cell Carcinoma

By Benzinga Newsdesk
Today, 4:42 PM
Opdivo demonstrated significant overall survival benefit over chemotherapy alone in both PD-L1 positive and all-randomized populations in both treatment arms CheckMate -648 marks the third global trial in which Opdivo

BMY

Read More
3 minute read

NANOBIOTIX Reports New Data For Potential First-In-Class Radioenhancer NBTXR3 In Combination With Anti-PD-1 Showing Local Or Distant Tumor Regression In 76.9% Of Evaluable Patients Regardless Of Prior Anti-PD-1 Exposure

By Benzinga Newsdesk
Today, 4:42 PM
Data to be Presented at the 2021 Annual Meeting of the American Society for Clinical Oncology Results show NBTXR3 plus radiotherapy could potentially stimulate immune response and convert anti-PD-1 non-responders into

NBTX

Read More
4 minute read

Ascendis Pharma’s VISEN Says Has Received Investigational New Drug Approval From Center For Drug Evaluation Of National Medical Products Administration For Phase 3 China Clinical Trial Of TransCon PTH Solution For Injection

By Benzinga Newsdesk
Today, 4:42 PM
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial 1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center

ASND